|
Neoplastic Syndromes, Hereditary
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.
|
27902461 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.
|
24310616 |
2014 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.
|
24310616 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While hAR allele did not grossly affect ETV1-induced neoplasia, ETV1 strongly antagonized global AR regulation and repressed critical androgen-induced differentiation and tumor suppressor genes, such as Nkx3-1 and Hoxb13.
|
25631336 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We used immunohistochemistry to analyze protein levels of HOXB13 in tumor samples from 912 postmenopausal node-negative breast cancer patients randomized to adjuvant tamoxifen therapy or no endocrine treatment.
|
20649975 |
2010 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer.
|
18794098 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer.
|
18794098 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We found that the polygenic PrCa risk score (PR score), calculated using the 71 known single-nucleotide polymorphisms (SNPs) associated with PrCa and the HOXB13 G84E variant act multiplicatively on PrCa risk.
|
25595936 |
2015 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found that the polygenic PrCa risk score (PR score), calculated using the 71 known single-nucleotide polymorphisms (SNPs) associated with PrCa and the HOXB13 G84E variant act multiplicatively on PrCa risk.
|
25595936 |
2015 |
|
Oestrogen receptor positive breast cancer
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52).
|
16609019 |
2006 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the prognostic value of the Breast Cancer Index (BCI), a continuous risk index based on a combination of HOXB13:IL17BR and molecular grade index, in women with early breast cancer treated with either tamoxifen alone or tamoxifen plus octreotide in the NCIC MA.14 phase III clinical trial (ClinicalTrials.gov Identifier NCT00002864; registered 1 November 1999).
|
26728744 |
2016 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the prognostic value of the Breast Cancer Index (BCI), a continuous risk index based on a combination of HOXB13:IL17BR and molecular grade index, in women with early breast cancer treated with either tamoxifen alone or tamoxifen plus octreotide in the NCIC MA.14 phase III clinical trial (ClinicalTrials.gov Identifier NCT00002864; registered 1 November 1999).
|
26728744 |
2016 |
|
Prostate cancer, familial
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the rs138213197" genes_norm="10481">G84E germline mutation (rs138213197) of HOXB13 in a case-control study of familial prostate cancer at Vanderbilt University (Nashville, TN) to independently evaluate the association of the mutation with familial prostate cancer.
|
22714738 |
2012 |
|
aggressive cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We believed that HOXB13/HOXC-AS3 signaling axis can be served as therapeutic targets for this highly aggressive cancer.
|
31062400 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
CTD_human |
We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.
|
23104005 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.
|
23104005 |
2012 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.
|
23104005 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Upregulation of HOXB13 was seen in malignant relative to borderline phyllodes tumors and further investigated by immunohistochemistry in a corresponding set of formalin-fixed, paraffin-embedded tumors.
|
20945089 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13.
|
31629417 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13.
|
31629417 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Unsupervised Principal Component Analysis (PCA) led to a focused core HOXB13 target gene-set referred to as HOTPAM9 (HOXB13 Targets separating Primary And Metastatic PCs).
|
31273254 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Unsupervised Principal Component Analysis (PCA) led to a focused core HOXB13 target gene-set referred to as HOTPAM9 (HOXB13 Targets separating Primary And Metastatic PCs).
|
31273254 |
2019 |